EMA Withdrawn: Pregabalin Zentiva k.s. (pregabalin) — Zentiva k.s.

View source ↗

Summary

The EMA withdrew pregabalin Zentiva k.s. from the market (Zentiva k.s.) with the therapeutic areas including anxiety disorders, neuralgia, and epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Epilepsy
• Neuropathic Pain

Drugs mentioned

• Pregabalin (Pregabalin)

Snippet

Status: Withdrawn. Therapeutic area: Anxiety Disorders;Neuralgia;Epilepsy. MAH: Zentiva k.s.. Decision date: 23/02/2023